Inhibition of both mutant and wild-type RAS-GTP in KRAS G12C colorectal cancer through cotreatment with G12C and EGFR inhibitors
T. McFall, M. Trogdon, L. Sisk-Hackworth, E. C. Stites
The paper shows that combining KRAS G12C and EGFR inhibitors inhibits both mutant and wild-type RAS, explaining their effectiveness in colorectal cancer.
bioRxiv · Oct 7, 2021Cancer Biology